BAYRY - Health Canada approves Bayer's Kerendia to treat kidney disease in diabetes patients

• Bayer ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) on Wednesday said Canada's drug regulator had approved its Kerendia medicine as an adjunct to standard of care for the treatment of chronic kidney disease (CKD) and type 2 diabetes (T2D).
• An adjunct is an additional treatment that is used to increase the efficacy or safety of a primary treatment.
• Kerendia would be used as an adjunct to standard of care therapy to reduce the risk of end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adults with CKD and T2D.
• The approval from Health Canada was based on results from two phase 3 trials, Bayer ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) said in a statement .
• Kerendia has been approved by the U.S. FDA.

For further details see: